WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC

This study is testing a combination of WAST cells (a type of immune cell therapy) plus docetaxel (a chemotherapy drug) for patients with advanced non-small cell lung cancer (NSCLC) whose disease has stopped responding to first-line immunotherapy (PD-1 inhibitors). The goal is to see if this combination can overcome resistance and improve outcomes. **You may be eligible if...** - You have advanced NSCLC confirmed by biopsy - Your cancer has progressed after receiving a PD-1 inhibitor as first-line treatment - You have at least one measurable tumor larger than 1 cm - You are in good general health (ECOG performance status 0 or 1) - Your blood counts, liver, and kidney function are within acceptable ranges - Your expected survival is greater than 3 months **You may NOT be eligible if...** - Your lung cancer has not progressed on prior PD-1 immunotherapy - You do not have measurable tumors on imaging - Your general health is too poor (ECOG above 1) - Your blood counts or organ function are outside acceptable ranges Talk to your doctor to see if this trial is right for you.